Comparison of adverse events associated with different spacers used with non-extrafine beclometasone dipropionate for asthma

Simon Wan Yau Ming, John Haughney, Dermot Ryan, Shishir Patel, Matthias Ochel, Martina Stagno d’Alcontres, Susannah Thornhill, Janwillem W.H. Kocks, David Price

Research output: Contribution to journalArticle

4 Downloads (Pure)

Abstract

Co-prescription of Aerochamber ® spacer with non-extrafine beclometasone diproprionate (non-EF BDP) is common but unlicensed. We report a comparison of inhaled corticosteroid (ICS)-related adverse events between patients co-prescribed Aerochamber compared to the licensed Volumatic ® spacer. We utilised two historical cohorts: questionnaire-based and electronic medical record (EMR)-based, to assess patient-reported and EMR-recorded adverse events in patients with asthma prescribed non-EF BDP. Marginal effect estimate (MEE) was calculated to determine non-inferiority of Aerochamber compared to Volumatic in terms of patient-reported oral thrush and hoarseness with margin of 0.13. Other patient-reported adverse events (sore throat, bruising, weight gain, and coughing), and EMR-recorded adverse events were also assessed. Rate of patient-reported oral adverse events were non-inferior in 385 patients prescribed Aerochamber compared to 155 patients prescribed Volumatic (27.7 vs 29.9%; MEE, −0.043; 95% CI, −0.133 to 0.047). Total patient-reported adverse events did not differ significantly between Aerochamber and Volumatic (53.3 vs 49.7% with ≥1 adverse event). The EMR-based study of 1471 matched pairs of subjects did not show significantly different number of EMR-recorded adverse events between Aerochamber and Volumatic (12.5 vs 12.8% with ≥1 adverse events). Co-prescribing Aerochamber with non-EF BDP does not increase the risk for patient-reported and EMR-recorded ICS-related adverse events compared to co-prescribing Volumatic.

Original languageEnglish
Article number3
Number of pages8
Journalnpj Primary Care Respiratory Medicine
Volume29
DOIs
Publication statusPublished - 8 Feb 2019

Fingerprint

Beclomethasone
Asthma
Electronic Health Records
Adrenal Cortex Hormones
Oral Candidiasis
Hoarseness
Pharyngitis
Weight Gain
Prescriptions

Keywords

  • METERED-DOSE INHALER
  • CORTICOSTEROID TREATMENT
  • FLUTICASONE PROPIONATE
  • COST-EFFECTIVENESS
  • ORAL CANDIDIASIS
  • REAL-LIFE
  • BECLOMETHASONE
  • EFFICACY
  • SAFETY
  • PRESCRIPTION

ASJC Scopus subject areas

  • Public Health, Environmental and Occupational Health
  • Pulmonary and Respiratory Medicine

Cite this

Comparison of adverse events associated with different spacers used with non-extrafine beclometasone dipropionate for asthma. / Ming, Simon Wan Yau; Haughney, John; Ryan, Dermot; Patel, Shishir; Ochel, Matthias; d’Alcontres, Martina Stagno; Thornhill, Susannah; Kocks, Janwillem W.H.; Price, David.

In: npj Primary Care Respiratory Medicine, Vol. 29, 3, 08.02.2019.

Research output: Contribution to journalArticle

Ming, Simon Wan Yau ; Haughney, John ; Ryan, Dermot ; Patel, Shishir ; Ochel, Matthias ; d’Alcontres, Martina Stagno ; Thornhill, Susannah ; Kocks, Janwillem W.H. ; Price, David. / Comparison of adverse events associated with different spacers used with non-extrafine beclometasone dipropionate for asthma. In: npj Primary Care Respiratory Medicine. 2019 ; Vol. 29.
@article{aee0a4ead4b84ec0a602aef10af844e2,
title = "Comparison of adverse events associated with different spacers used with non-extrafine beclometasone dipropionate for asthma",
abstract = "Co-prescription of Aerochamber {\circledR} spacer with non-extrafine beclometasone diproprionate (non-EF BDP) is common but unlicensed. We report a comparison of inhaled corticosteroid (ICS)-related adverse events between patients co-prescribed Aerochamber compared to the licensed Volumatic {\circledR} spacer. We utilised two historical cohorts: questionnaire-based and electronic medical record (EMR)-based, to assess patient-reported and EMR-recorded adverse events in patients with asthma prescribed non-EF BDP. Marginal effect estimate (MEE) was calculated to determine non-inferiority of Aerochamber compared to Volumatic in terms of patient-reported oral thrush and hoarseness with margin of 0.13. Other patient-reported adverse events (sore throat, bruising, weight gain, and coughing), and EMR-recorded adverse events were also assessed. Rate of patient-reported oral adverse events were non-inferior in 385 patients prescribed Aerochamber compared to 155 patients prescribed Volumatic (27.7 vs 29.9{\%}; MEE, −0.043; 95{\%} CI, −0.133 to 0.047). Total patient-reported adverse events did not differ significantly between Aerochamber and Volumatic (53.3 vs 49.7{\%} with ≥1 adverse event). The EMR-based study of 1471 matched pairs of subjects did not show significantly different number of EMR-recorded adverse events between Aerochamber and Volumatic (12.5 vs 12.8{\%} with ≥1 adverse events). Co-prescribing Aerochamber with non-EF BDP does not increase the risk for patient-reported and EMR-recorded ICS-related adverse events compared to co-prescribing Volumatic.",
keywords = "METERED-DOSE INHALER, CORTICOSTEROID TREATMENT, FLUTICASONE PROPIONATE, COST-EFFECTIVENESS, ORAL CANDIDIASIS, REAL-LIFE, BECLOMETHASONE, EFFICACY, SAFETY, PRESCRIPTION",
author = "Ming, {Simon Wan Yau} and John Haughney and Dermot Ryan and Shishir Patel and Matthias Ochel and d’Alcontres, {Martina Stagno} and Susannah Thornhill and Kocks, {Janwillem W.H.} and David Price",
note = "The authors would like to extend their acknowledgement to Dr. Antony Hardjojo for proof-reading this manuscript. This study is funded by Chiesi Limited.",
year = "2019",
month = "2",
day = "8",
doi = "10.1038/s41533-019-0115-0",
language = "English",
volume = "29",
journal = "npj Primary Care Respiratory Medicine",
issn = "2055-1010",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - Comparison of adverse events associated with different spacers used with non-extrafine beclometasone dipropionate for asthma

AU - Ming, Simon Wan Yau

AU - Haughney, John

AU - Ryan, Dermot

AU - Patel, Shishir

AU - Ochel, Matthias

AU - d’Alcontres, Martina Stagno

AU - Thornhill, Susannah

AU - Kocks, Janwillem W.H.

AU - Price, David

N1 - The authors would like to extend their acknowledgement to Dr. Antony Hardjojo for proof-reading this manuscript. This study is funded by Chiesi Limited.

PY - 2019/2/8

Y1 - 2019/2/8

N2 - Co-prescription of Aerochamber ® spacer with non-extrafine beclometasone diproprionate (non-EF BDP) is common but unlicensed. We report a comparison of inhaled corticosteroid (ICS)-related adverse events between patients co-prescribed Aerochamber compared to the licensed Volumatic ® spacer. We utilised two historical cohorts: questionnaire-based and electronic medical record (EMR)-based, to assess patient-reported and EMR-recorded adverse events in patients with asthma prescribed non-EF BDP. Marginal effect estimate (MEE) was calculated to determine non-inferiority of Aerochamber compared to Volumatic in terms of patient-reported oral thrush and hoarseness with margin of 0.13. Other patient-reported adverse events (sore throat, bruising, weight gain, and coughing), and EMR-recorded adverse events were also assessed. Rate of patient-reported oral adverse events were non-inferior in 385 patients prescribed Aerochamber compared to 155 patients prescribed Volumatic (27.7 vs 29.9%; MEE, −0.043; 95% CI, −0.133 to 0.047). Total patient-reported adverse events did not differ significantly between Aerochamber and Volumatic (53.3 vs 49.7% with ≥1 adverse event). The EMR-based study of 1471 matched pairs of subjects did not show significantly different number of EMR-recorded adverse events between Aerochamber and Volumatic (12.5 vs 12.8% with ≥1 adverse events). Co-prescribing Aerochamber with non-EF BDP does not increase the risk for patient-reported and EMR-recorded ICS-related adverse events compared to co-prescribing Volumatic.

AB - Co-prescription of Aerochamber ® spacer with non-extrafine beclometasone diproprionate (non-EF BDP) is common but unlicensed. We report a comparison of inhaled corticosteroid (ICS)-related adverse events between patients co-prescribed Aerochamber compared to the licensed Volumatic ® spacer. We utilised two historical cohorts: questionnaire-based and electronic medical record (EMR)-based, to assess patient-reported and EMR-recorded adverse events in patients with asthma prescribed non-EF BDP. Marginal effect estimate (MEE) was calculated to determine non-inferiority of Aerochamber compared to Volumatic in terms of patient-reported oral thrush and hoarseness with margin of 0.13. Other patient-reported adverse events (sore throat, bruising, weight gain, and coughing), and EMR-recorded adverse events were also assessed. Rate of patient-reported oral adverse events were non-inferior in 385 patients prescribed Aerochamber compared to 155 patients prescribed Volumatic (27.7 vs 29.9%; MEE, −0.043; 95% CI, −0.133 to 0.047). Total patient-reported adverse events did not differ significantly between Aerochamber and Volumatic (53.3 vs 49.7% with ≥1 adverse event). The EMR-based study of 1471 matched pairs of subjects did not show significantly different number of EMR-recorded adverse events between Aerochamber and Volumatic (12.5 vs 12.8% with ≥1 adverse events). Co-prescribing Aerochamber with non-EF BDP does not increase the risk for patient-reported and EMR-recorded ICS-related adverse events compared to co-prescribing Volumatic.

KW - METERED-DOSE INHALER

KW - CORTICOSTEROID TREATMENT

KW - FLUTICASONE PROPIONATE

KW - COST-EFFECTIVENESS

KW - ORAL CANDIDIASIS

KW - REAL-LIFE

KW - BECLOMETHASONE

KW - EFFICACY

KW - SAFETY

KW - PRESCRIPTION

UR - http://www.scopus.com/inward/record.url?scp=85061264881&partnerID=8YFLogxK

UR - http://www.mendeley.com/research/comparison-adverse-events-associated-different-spacers-used-nonextrafine-beclometasone-dipropionate

U2 - 10.1038/s41533-019-0115-0

DO - 10.1038/s41533-019-0115-0

M3 - Article

VL - 29

JO - npj Primary Care Respiratory Medicine

JF - npj Primary Care Respiratory Medicine

SN - 2055-1010

M1 - 3

ER -